Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Common (typically mild and transient): Increased appetite (moderate, less than GHRP-6) Flushing and warmth at the injection site or face Transient drowsiness or sleepiness, particularly with evening doses Mild water retention and peripheral edema Increased gastrointestinal motility Less Common: Elevations in cortisol and ACTH (moderate, comparable to hCRH) Mild prolactin elevation (less than TRH-induced levels) Numbness or tingling in extremities Joint stiffness Lightheadedness post-injection Rare or Theoretical Concerns: Impaired glucose metabolism and elevated blood glucose with prolonged use Potential tachyphylaxis (reduced response) with continuous daily dosing Theoretical promotion of existing malignancies through elevated GH/IGF-1 (applies to all GH-elevating compounds) Side effect incidence tends to be lower than with exogenous hGH because GHRP-2 stimulates endogenous GH synthesis within physiological regulatory limits
Lets get in touch
Myostatin, also known as growth differentiation factor 8, affects muscle mass by reducing protein synthesis and muscle growth, thus preventing unwanted hypertrophy [3]
This leads to effective skin lightening, reduction in pigmentation, and a brighter, more radiant complexion with consistent use
It has been investigated for its potential involvement in regulating sleep patterns, neuroendocrine function, and stress-related hormone signaling
We are transparent that conventional medicine does not classify it as a formal diagnosis
